HOLX · As filed with the SEC
Hologic cash flow statement, by fiscal year
The statement as Hologic presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2025 Year ended Sep 27, 2025 | FY2024 Year ended Sep 28, 2024 | FY2023 Year ended Sep 30, 2023 | FY2022 Year ended Sep 24, 2022 | FY2021 Year ended Sep 25, 2021 | FY2020 Year ended Sep 26, 2020 | FY2019 Year ended Sep 28, 2019 | FY2018 Year ended Sep 29, 2018 |
|---|---|---|---|---|---|---|---|---|
| OPERATING ACTIVITIES | ||||||||
| Net (loss) income | — | — | — | — | — | — | (203,600,000) | (111,300,000) |
| Net income | 565,700,000 | 789,500,000 | 456,000,000 | 1,302,000,000 | 1,869,700,000 | 1,110,500,000 | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation | 108,900,000 | 99,300,000 | 89,600,000 | 89,200,000 | 88,000,000 | 83,100,000 | 92,500,000 | 101,600,000 |
| Amortization of acquired intangible assets | 190,900,000 | 209,700,000 | 233,800,000 | 340,900,000 | 318,900,000 | 292,900,000 | 370,600,000 | 378,700,000 |
| Non-cash interest expense | — | — | — | — | — | — | 8,600,000 | 15,000,000 |
| Stock-based compensation expense | 84,300,000 | 82,300,000 | 79,600,000 | 66,700,000 | 65,000,000 | 83,300,000 | 62,000,000 | 65,000,000 |
| Deferred income taxes and other non-cash taxes | (141,600,000) | (72,100,000) | (109,100,000) | (166,200,000) | (70,100,000) | (94,400,000) | (235,700,000) | (477,300,000) |
| Goodwill impairment charge | — | — | — | — | — | 0 | 0 | 685,700,000 |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | — | — | — | — | — | — | — | 46,000,000 |
| Intangible assets and equipment impairment charges | 225,900,000 | 44,800,000 | 223,800,000 | 45,100,000 | 0 | 30,200,000 | 685,400,000 | — |
| Fair value write-up of inventory sold | — | — | — | — | — | — | 7,100,000 | 1,100,000 |
| Loss on assets held-for-sale | 0 | 0 | 51,700,000 | — | — | — | — | — |
| Contingent consideration fair value adjustments | 0 | 1,700,000 | (14,900,000) | (39,500,000) | — | — | — | — |
| Debt extinguishment loss | — | 0 | 0 | 700,000 | 21,600,000 | 0 | 800,000 | 45,900,000 |
| Gain on sale of business | — | — | — | — | — | — | 0 | 0 |
| Gain on sale of investments | — | — | — | — | — | — | — | 0 |
| Other adjustments and non-cash items | 43,400,000 | 45,900,000 | 28,900,000 | 32,600,000 | 24,300,000 | 27,300,000 | 18,100,000 | 8,700,000 |
| Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions: | ||||||||
| Accounts receivable | 7,800,000 | 41,000,000 | (1,500,000) | 272,300,000 | 110,900,000 | (427,100,000) | (76,500,000) | (38,200,000) |
| Inventory | (1,300,000) | (47,400,000) | (4,900,000) | (136,600,000) | (84,100,000) | (25,300,000) | (63,000,000) | (50,600,000) |
| Prepaid income taxes | 20,100,000 | (21,700,000) | 17,400,000 | (23,300,000) | 13,000,000 | (3,800,000) | (3,200,000) | (9,400,000) |
| Prepaid expenses and other assets | 11,900,000 | 7,300,000 | 23,600,000 | 384,300,000 | (56,300,000) | (286,200,000) | (6,000,000) | (4,200,000) |
| Accounts payable | (11,300,000) | 22,200,000 | (23,000,000) | (14,400,000) | 20,400,000 | (4,900,000) | (5,500,000) | 23,900,000 |
| Accrued expenses and other liabilities | (32,300,000) | 73,400,000 | (14,200,000) | (15,800,000) | (4,900,000) | 96,000,000 | (16,500,000) | 53,800,000 |
| Deferred revenue | (15,300,000) | 9,300,000 | 14,400,000 | (12,300,000) | 14,000,000 | 15,000,000 | 14,400,000 | (1,500,000) |
| Net cash provided by operating activities | 1,057,100,000 | 1,285,200,000 | 1,051,200,000 | 2,125,700,000 | 2,330,400,000 | 896,600,000 | 649,500,000 | 732,900,000 |
| INVESTING ACTIVITIES | ||||||||
| Acquisition of businesses, net of cash acquired | (321,500,000) | (297,300,000) | (5,000,000) | (158,600,000) | (1,164,700,000) | (119,400,000) | (110,600,000) | (76,500,000) |
| Net proceeds from sale of business | — | — | — | 0 | 0 | 139,300,000 | 0 | 0 |
| Sale of business, net of cash disposed | 0 | (31,300,000) | — | — | — | — | — | — |
| Purchases of available-for-sale securities | (146,900,000) | (267,700,000) | — | — | — | — | — | — |
| Maturities of available-for-sale securities | 176,000,000 | — | — | — | — | — | — | — |
| Capital expenditures | (58,800,000) | (72,400,000) | (91,800,000) | (70,600,000) | (96,800,000) | (98,300,000) | (57,000,000) | (58,400,000) |
| Proceeds from the Department of Defense | 0 | 0 | 20,500,000 | 75,000,000 | — | — | — | — |
| Increase in equipment under customer usage agreements | (78,200,000) | (57,800,000) | (58,400,000) | (56,600,000) | (59,400,000) | (58,100,000) | (52,100,000) | (47,200,000) |
| Proceeds from sale of available-for-sale marketable securities | — | — | — | — | — | — | 0 | 100,000 |
| Purchase of cost method investment | — | — | — | — | — | 0 | (3,000,000) | (6,000,000) |
| Purchases of insurance contracts | — | — | — | — | — | — | — | 0 |
| Sales of mutual funds | — | — | — | — | — | — | — | 0 |
| Payments to Acquire in Process Research and Development | — | — | — | — | — | — | 4,500,000 | — |
| Purchase of insurance contracts | — | — | — | — | — | (2,400,000) | — | — |
| Purchase of equity method investment | — | — | (10,000,000) | — | 0 | 0 | (18,200,000) | — |
| Loans to SSI | — | — | — | — | 0 | 0 | (28,400,000) | — |
| Strategic investments | (35,000,000) | (42,500,000) | — | — | — | — | — | — |
| Purchase of intellectual property | (15,400,000) | (10,000,000) | 0 | 0 | 6,500,000 | 0 | — | — |
| Other activity | — | — | — | 4,500,000 | (2,200,000) | (2,700,000) | (6,900,000) | (7,200,000) |
| Other activity | (2,900,000) | (2,000,000) | (7,400,000) | — | — | — | — | — |
| Net cash used in investing activities | (482,700,000) | (781,000,000) | (152,100,000) | (206,300,000) | (1,329,600,000) | (141,600,000) | (280,700,000) | (195,200,000) |
| FINANCING ACTIVITIES | ||||||||
| Proceeds from long-term debt, net of issuance costs | 1,161,000,000 | 0 | 0 | 1,491,200,000 | 0 | 0 | 1,500,000,000 | 1,500,000,000 |
| Repayment of long-term debt | — | — | — | — | — | — | (1,462,500,000) | (1,359,400,000) |
| Repayment of long-term debt | (1,197,500,000) | (287,500,000) | (15,000,000) | (1,387,500,000) | (75,000,000) | (37,500,000) | — | — |
| Proceeds from Senior Notes | — | — | 0 | 0 | 936,300,000 | 0 | 0 | 1,350,000,000 |
| Repayment of Senior Notes | — | — | 0 | 0 | (970,800,000) | 0 | 0 | (1,037,700,000) |
| Payments to extinguish convertible notes | — | — | — | — | — | 0 | 0 | (546,200,000) |
| Proceeds from revolving credit line | — | — | — | 0 | 0 | 750,000,000 | 480,000,000 | 1,150,000,000 |
| Repayments under revolving credit line | — | — | 0 | 0 | (250,000,000) | (500,000,000) | (780,000,000) | (1,195,000,000) |
| Proceeds from accounts receivable securitization agreement | — | — | 0 | 0 | 320,000,000 | 16,000,000 | 43,000,000 | 34,000,000 |
| Repayments under accounts receivable securitization agreement | — | 0 | 0 | (248,500,000) | (71,500,000) | (250,000,000) | (34,000,000) | (9,000,000) |
| Repayment of acquired long-term debt | — | 0 | 0 | (63,700,000) | — | (8,300,000) | (2,500,000) | (3,300,000) |
| Payments to Noncontrolling Interests | — | — | 0 | 0 | (8,500,000) | (1,800,000) | — | — |
| Payment of contingent consideration | (1,100,000) | (2,600,000) | (7,600,000) | (12,200,000) | — | (24,300,000) | (6,500,000) | — |
| Payment of deferred acquisition consideration | 0 | 0 | (800,000) | 0 | 1,900,000 | — | — | — |
| Purchase of interest rate caps | — | — | — | — | 0 | 0 | (1,500,000) | (3,700,000) |
| Repurchases of common stock | (752,900,000) | (835,100,000) | (474,800,000) | (542,100,000) | (409,800,000) | (653,600,000) | (200,100,000) | (275,800,000) |
| Payment of debt issuance costs | — | — | — | — | — | 0 | (2,700,000) | (23,500,000) |
| Net proceeds from issuance of common stock under employee stock plans | 38,800,000 | 37,800,000 | 43,000,000 | 33,500,000 | 51,300,000 | 65,600,000 | 49,800,000 | 33,200,000 |
| Payments under finance lease obligations | — | — | — | — | — | (1,700,000) | (1,700,000) | (1,700,000) |
| Payment of minimum tax withholdings on net share settlements of equity awards | (22,200,000) | (17,400,000) | (24,000,000) | (22,900,000) | (47,500,000) | (14,300,000) | (12,800,000) | (16,700,000) |
| Payments under finance lease obligations | (3,300,000) | (3,800,000) | (4,000,000) | (3,800,000) | 2,400,000 | — | — | — |
| Net cash used in financing activities | (777,200,000) | (1,108,600,000) | (483,200,000) | (756,000,000) | (529,800,000) | (659,900,000) | (431,500,000) | (404,800,000) |
| Effect of exchange rate changes on cash and cash equivalents | — | — | — | — | — | — | (2,200,000) | (6,800,000) |
| Net (decrease) increase in cash and cash equivalents | — | — | — | — | — | — | (64,900,000) | 126,100,000 |
| Cash and cash equivalents, beginning of period | — | — | — | — | — | 601,800,000 | 666,700,000 | 540,600,000 |
| Cash and cash equivalents, end of period | — | — | — | — | — | — | 601,800,000 | 666,700,000 |
| Effect of exchange rate changes on cash and cash equivalents | 2,100,000 | 8,900,000 | 300,000 | 5,800,000 | (1,700,000) | 4,100,000 | — | — |
| Net increase (decrease) in cash and cash equivalents | (200,700,000) | (595,500,000) | 416,200,000 | 1,169,200,000 | 469,300,000 | 99,200,000 | — | — |
| Cash and cash equivalents, beginning of period | 2,160,200,000 | 2,755,700,000 | 2,339,500,000 | 1,170,300,000 | 701,000,000 | 601,800,000 | 666,700,000 | — |
| Cash and cash equivalents, end of period | 1,959,500,000 | 2,160,200,000 | 2,755,700,000 | 2,339,500,000 | 1,170,300,000 | 701,000,000 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.